Sight Sciences, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
SGHT Nasdaq 3850 www.sightsciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sight Sciences, Inc.

April 2025's Top Penny Stocks To Watch - Apr 10th, 2025 6:05 pm
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th - Mar 25th, 2025 8:05 pm
Q4 2024 Sight Sciences Inc Earnings Call - Mar 6th, 2025 5:09 pm
Sight Sciences Inc (SGHT) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Challenges - Mar 6th, 2025 7:11 am
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics - Mar 5th, 2025 11:00 pm
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates - Mar 5th, 2025 10:20 pm
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance - Mar 5th, 2025 9:05 pm
March 2025 Penny Stocks To Consider For Growth - Mar 3rd, 2025 5:04 pm
Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know - Feb 26th, 2025 3:00 pm
Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting - Feb 24th, 2025 9:05 pm
Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 - Feb 19th, 2025 9:05 pm
Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day - Feb 13th, 2025 9:05 pm
Promising US Penny Stocks To Consider In January 2025 - Jan 24th, 2025 8:10 pm
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights - Jan 14th, 2025 1:00 pm
Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma - Jan 7th, 2025 9:05 pm
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options - Dec 19th, 2024 9:05 pm
Sight Sciences initiated with a Buy at UBS - Dec 7th, 2024 10:31 am
Nano Dimension Leads 3 US Penny Stocks To Consider - Nov 25th, 2024 8:04 pm
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference - Nov 19th, 2024 9:05 pm
Inside a $400 billion bet on the brain-computer interface revolution - Nov 18th, 2024 3:00 pm